Related Experiment Videos
D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal
1Department of Psychiatry, Hokkaido University School of Medicine, Kita 15, Nishi 7, Kitaku, 060-8638, Sapporo, Japan.
Abstract:
The present study examined effect of administration of a selective D1 dopamine receptor agonist, SKF38393 on extracellular concentrations of glutamate (Glu) and gamma-aminobutyric acid (GABA) in mPFC, by using in vivo microdialysis. Perfusion with SKF38393 via a dialysis probe reduced concentrations of both Glu and GABA dose-relatedly, and these effects were prevented by co-perfusion with a D1 dopamine receptor antagonist, SCH23390 (40 microM). These results suggested that the dopaminergic hyperactivity may lead to the hypofunction of glutamatergic and GABAergic systems in mPFC via D1 dopamine receptor stimulation.
Insights
Dopamine D1 receptor stimulation by SKF38393 reduces glutamate and GABA in the medial prefrontal cortex. These effects are blocked by the D1 antagonist SCH23390, suggesting D1 receptors mediate dopamine
Area of Science:
- Neuroscience
- Dopamine Receptor Research
- Neurotransmitter Systems
Background:
- The medial prefrontal cortex (mPFC) is crucial for cognitive functions.
- Dopamine signaling, particularly via D1 receptors, modulates mPFC activity.
- Imbalances in glutamate (Glu) and gamma-aminobutyric acid (GABA) are implicated in neurological disorders.
Purpose of the Study:
- To investigate the impact of selective D1 dopamine receptor agonist SKF38393 on extracellular Glu and GABA levels in the mPFC.
- To elucidate the role of D1 dopamine receptors in regulating glutamatergic and GABAergic neurotransmission within the mPFC.
Main Methods:
- In vivo microdialysis was employed to measure extracellular neurotransmitter concentrations in the rat mPFC.
- Administration of SKF38393 (a D1 agonist) and SCH23390 (a D1 antagonist) via a dialysis probe.
- Dose-response analysis of SKF38393 effects and blockade by SCH23390.
Main Results:
- Perfusion with SKF38393 led to a dose-dependent reduction in extracellular Glu and GABA concentrations in the mPFC.
- Co-perfusion with the D1 antagonist SCH23390 prevented the SKF38393-induced decrease in Glu and GABA.
- These findings indicate a direct role for D1 receptor stimulation in modulating these key neurotransmitters.
Conclusions:
- Dopaminergic hyperactivity, mediated by D1 receptor stimulation, may result in the hypofunction of glutamatergic and GABAergic systems in the mPFC.
- D1 dopamine receptors are critical regulators of the balance between excitatory and inhibitory neurotransmission in the mPFC.
- Understanding this interaction is vital for developing therapeutic strategies for mPFC-related cognitive and psychiatric disorders.